

FAVORIT - Publications

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Bostom AG, Carpenter MA, Kusek JW, et al. *Am Heart J* 2006; 152:448.e1-e7.

Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Bostom AG, Carpenter MA, Hunsicker L, et al. *American Journal of Kidney Diseases*, January 2009, Volume 53, Issue 1, Pages 121-128.

Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients. Bostom AG, Carpenter MA, Kusek JW, et al. *Circulation*. 2011 Apr 26; 123(16):1763-70.

Cognitive Dysfunction and Depression in Adult Kidney Transplant Recipients: Baseline Findings from the FAVORIT Ancillary Cognitive Trial (FACT). Troen, Scott, D'Anci, Moorthy, et al. *Journal of Renal Nutrition* 2011; 22:2. 268-276.

Inadequacy of cardiovascular risk factor management in chronic kidney transplantation – evidence from the FAVORIT study. Carpenter, Weir, Adey, et al. *Clinical Transplantation* 2012; 26:2: E438-E446.

Kidney Function and Risk of Cardiovascular Disease and Mortality in Kidney Transplant Recipients: The FAVORIT Trial. Weiner, Carpenter, Levey, et al. *American Journal of Transplantation* 2012; Retrieved from DOI: 10.1111/j.1600-6143.2012.04101.x

Abstracts and Presentations (partial list)

Adding New Sites to a Multinational Trial. Carpenter MA, Bostom AG, Pacheco-Silva A, et al. *Society for Clinical Trials* 2007; May 20, 2007 Montreal, Canada.

Logistical Challenges of including a Brazilian Site in a Clinical Trial Based in the United States. Reeves L, Gravens-Mueller L, Carpenter MA, et al. *Society for Clinical Trials* 2007; May 20, 2007 Montreal, Canada.

Ancillary Study Resources Available in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial of Kidney Graft Recipients. Carpenter MA, Bostom AG, Kusek JW, et al. *American Society of Nephrology Renal Week* 2008; November 4 - 9, 2008; Philadelphia, PA.

Replicate Blood Sampling for Laboratory Quality Control in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Reeves L, Gravens-Mueller L, Carpenter MA, et al. *Society for Clinical Trials* 2009; May 3, 2009 Atlanta, GA.

Homocysteine-lowering in chronic stable renal transplant recipients: The FAVORIT trial. Bostom AG, et al. *American Society of Nephrology Renal Week* 2009; October 30, 2009; San Diego, CA.

Cardiovascular Disease in Kidney Transplant Recipients: Risk Factors and CVD Events in FAVORIT, Levey P, Carpenter MA, Bostom AG et al. Submitted to the Nutrition, Physical Activity and Metabolism/Cardiovascular Disease Epidemiology and Prevention 2011 Scientific Sessions; March 22, 2011; Atlanta, GA.

Impact of Uncontrolled Hypertension on Risk of Cardiovascular Disease and Renal Failure in Kidney Transplant Recipients. Carpenter MA, Bostom AG, Kusek JW, et al. Submitted to the American Transplant Congress 2011; April 20, 2011; Philadelphia, PA.

Current trends in drug therapy for stable renal transplant recipients, Carpenter MA, Bostom AG, Kusek JW, et al. Accepted to the National Kidney Foundation 2011 Spring Clinical Meeting; April 26, 2011; Las Vegas, NV.

Does Physical Activity Reflect Cardiovascular Health Status in Patients with Chronic Kidney Disease? Garber, C, Campbell, S, Bostom AG, et al. Submitted to the American College of Sports Medicine Annual Meeting 2011; May 31, 2011; Denver CO.